dc.contributor.author | Bai, Xilian | |
dc.contributor.author | Borrow, Ray | |
dc.contributor.author | Bukovski, Suzana | |
dc.contributor.author | Caugant, Dominique A | |
dc.contributor.author | Culic, Davor | |
dc.contributor.author | Delic, Snezana | |
dc.contributor.author | Dinleyici, Ener Cagri | |
dc.contributor.author | Eloshvili, Medeia | |
dc.contributor.author | Erdősi, Tímea | |
dc.contributor.author | Galajeva, Jelena | |
dc.contributor.author | Křížová, Pavla | |
dc.contributor.author | Lucidarme, Jay | |
dc.contributor.author | Mironov, Konstantin | |
dc.contributor.author | Nurmatov, Zuridin | |
dc.contributor.author | Pana, Marina | |
dc.contributor.author | Rahimov, Erkin | |
dc.contributor.author | Savrasova, Larisa | |
dc.contributor.author | Skoczyńska, Anna | |
dc.contributor.author | Smith, Vinny | |
dc.contributor.author | Taha, Muhamed-Kheir | |
dc.contributor.author | Titov, Leonid | |
dc.contributor.author | Vazquez-Moreno, Julio Alberto | |
dc.contributor.author | Yeraliyeva, Lyazzat | |
dc.date.accessioned | 2022-03-25T11:13:56Z | |
dc.date.available | 2022-03-25T11:13:56Z | |
dc.date.issued | 2019-12 | |
dc.identifier.citation | J Infect. 2019 Dec;79(6):528-541. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/13817 | |
dc.description | Authors would like to thank Dr Olivier Ronveaux (Infectious Hazard Management, World Health Organization, Geneva, Switzerland) for his contributions during this GMI Roundtable Meeting and for providing permission to use his presentation content in this manuscript. The authors were assisted in the preparation of the manuscript by Hannah Birchby, a professional medical writer at CircleScience, an Ashfield Company, part of UDG Healthcare plc. Medical writing support was funded by Sanofi Pasteur. | es_ES |
dc.description.abstract | The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Antibiotic resistance | es_ES |
dc.subject | Bacterial meningitis | es_ES |
dc.subject | Conjugate vaccine | es_ES |
dc.subject | Eastern Europe | es_ES |
dc.subject | High-risk groups | es_ES |
dc.subject | Immunization program | es_ES |
dc.subject | Meningococcal disease | es_ES |
dc.subject | Neisseria meningitidis | es_ES |
dc.subject | Polysaccharide vaccine | es_ES |
dc.subject | Refugees | es_ES |
dc.subject.mesh | Disease Outbreaks | es_ES |
dc.subject.mesh | Carrier State | es_ES |
dc.subject.mesh | Communicable Disease Control | es_ES |
dc.subject.mesh | Disease Transmission, Infectious | es_ES |
dc.subject.mesh | Europe, Eastern | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Incidence | es_ES |
dc.subject.mesh | Meningococcal Infections | es_ES |
dc.subject.mesh | Meningococcal Vaccines | es_ES |
dc.subject.mesh | Neisseria meningitidis | es_ES |
dc.subject.mesh | Serogroup | es_ES |
dc.title | Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 31682877 | es_ES |
dc.format.volume | 79 | es_ES |
dc.format.number | 6 | es_ES |
dc.format.page | 528-541 | es_ES |
dc.identifier.doi | 10.1016/j.jinf.2019.10.018 | es_ES |
dc.contributor.funder | Sanofi Pasteur | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1532-2742 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.jinf.2019.10.018 | es_ES |
dc.identifier.journal | The Journal of Infection | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |